论文部分内容阅读
现在国内各个行业和领域中,外资及合资企业享受的各种有形和无形的超国民待遇过多,严重挤压了国内企业的生存和发展空间,造成市场竞争的不公平。而我国企业在国外则连普通国民待遇也享受不到,对比反差很大。以医药行业为例,外资企业享受着从自主定价、招标优惠、市场准入,到宽松的监管核查和进口注册等系列超国民待遇,这使原来就处于相对弱势的国内医药企业处于不公平市场环境中,发展步履艰难,同时也是造成“看病贵”这一民生难题的重要原因。
Nowadays, all kinds of tangible and intangible super-national treatment enjoyed by foreign capital and joint ventures in various industries and fields all over the country have seriously squeezed the space for the survival and development of domestic enterprises and caused unfair market competition. However, our country’s enterprises do not enjoy even the common national treatment in foreign countries, and their contrasts are quite different. Taking the pharmaceutical industry as an example, foreign-funded enterprises enjoy a series of super-national treatment ranging from voluntary pricing, invitation to tender, market access, to loose regulatory verification and import registration, which makes the original domestic pharmaceutical enterprises in an unfair position unfairly in the market Environment, the development of difficult walking, but also contributed to the “expensive” the important reason for this difficult problem of livelihood.